Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Fennec Pharma’s partner Norgine Pharma launches Pedmarqsi in Germany: Monday, February 10, 2025, 14:00 Hrs [IST] Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...